Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
Macrogen, Inc. specializes in genomic and bioinformatics services, primarily operating in South Korea and expanding into global markets. The company leverages its proprietary technologies in next-generation sequencing and bioinformatics to provide personalized medicine solutions, setting it apart from competitors.
HealthcareBiotechnologymoderate - The company has significant fixed costs associated with its laboratory operations but benefits from economies of scale as it increases its volume of genomic tests.
Business Overview
01Genomic testing services - 60%
02Bioinformatics solutions - 25%
03Research and development services - 15%
Macrogen generates revenue through a combination of genomic testing services, which include whole genome sequencing and targeted gene panels, and bioinformatics solutions that provide data analysis and interpretation. Its competitive advantage lies in its advanced sequencing technology and established partnerships with research institutions, allowing for high-quality, rapid results.
What Moves the Stock
Advancements in genomic technology adoption rates
Regulatory approvals for new testing services
Partnerships with pharmaceutical companies for drug development
Market expansion into North America and Europe
Watch on Earnings
Revenue from genomic testing servicesGross margin percentageYear-over-year growth in bioinformatics revenue